SEC Comment Letter 0000000000-25-000426 to Marker Therapeutics, Inc. (MRKR) (CIK 0001094038) (MRKR)
Marker Therapeutics, Inc. (MRKR) (CIK 0001094038)
Date: Jan. 15, 2025 · CIK: 0001094038 · Accession: 0000000000-25-000426
AI Filing Summary & Sentiment
File numbers found in text: 333-284233
Letter
January 15, 2025 Juan Vera Chief Executive Officer Marker Therapeutics, Inc. 2450 Holcombe Blvd, Suite BCM-A, MS: BCM251 Houston, TX 77021 Re:Marker Therapeutics, Inc. Registration Statement on Form S-3 Filed January 10, 2025 File No. 333-284233 Dear Juan Vera: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jessica Dickerson at 202-551-8013 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Mark A. Catchur, Esq.
Show Raw Text
January 15, 2025
Juan Vera
Chief Executive Officer
Marker Therapeutics, Inc.
2450 Holcombe Blvd, Suite BCM-A, MS: BCM251
Houston, TX 77021
Re:Marker Therapeutics, Inc.
Registration Statement on Form S-3
Filed January 10, 2025
File No. 333-284233
Dear Juan Vera:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Jessica Dickerson at 202-551-8013 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Mark A. Catchur, Esq.